Page 122 - 《中国药房》2025年7期

分级与结果解读：方法与案例[J]. 中国循证医学杂志， safety of a fixed-ratio combination of insulin degludec and
2024，24（10）：1231-1240. liraglutide（IDegLira） compared with its components
[12] YUAN X Y，GUO X H，ZHANG J Q，et al. Improved gly‐ given alone：results of a phase 3，open-label，randomised，
caemic control and weight benefit with iGlarLixi versus 26-week，treat-to-target trial in insulin-naive patients with
insulin glargine 100 U/mL in Chinese people with type 2 type 2 diabetes[J]. Lancet Diabetes Endocrinol，2014，2
diabetes advancing their therapy from basal insulin plus （11）：885-893.
oral antihyperglycaemic drugs：results from the LixiLan-L- [21] LINGVAY I，MANGHI F P，GARCÍA-HERNÁNDEZ P，
CN randomized controlled trial[J]. Diabetes Obes Metab， et al. Effect of insulin glargine up-titration vs insulin de‐
2022，24（11）：2182-2191. gludec/liraglutide on glycated hemoglobin levels in pa‐
[13] YANG W Y，DONG X L，LI Q J，et al. Efficacy and tients with uncontrolled type 2 diabetes：the DUAL V ran‐
safety benefits of iGlarLixi versus insulin glargine 100 domized clinical trial[J]. JAMA，2016，315（9）：898-907.
U/mL or lixisenatide in Asian Pacific people with subopti‐ [22] 母义明，郭立新，李玲，等. 德谷胰岛素和甘精胰岛素在
mally controlled type 2 diabetes on oral agents：the 未经胰岛素治疗的 2 型糖尿病受试者中的疗效和安全
LixiLan-O-AP randomized controlled trial[J]. Diabetes 性比较：一项国际多中心随机对照研究的中国亚组结果
Obes Metab，2022，24（8）：1522-1533. [J]. 中华内科杂志，2017，56（9）：660-666.
[14] TERAUCHI Y，NAKAMA T，SPRANGER R，et al. Effi‐ [23] ROSENSTOCK J，CHENG A，RITZEL R，et al. More
cacy and safety of insulin glargine/lixisenatide fixed-ratio similarities than differences testing insulin glargine 300
combination（iGlarLixi 1∶1） in Japanese patients with units/mL versus insulin degludec 100 units/mL in insulin-
type 2 diabetes mellitus inadequately controlled on oral naive type 2 diabetes：the randomized head-to-head
antidiabetic drugs：a randomized，26-week，open-label， BRIGHT trial[J]. Diabetes Care，2018，41（10）：2147-2154.
multicentre study：the LixiLan JP-O2 randomized clinical [24] PAN C Y，GROSS J L，YANG W Y，et al. A multina‐
trial[J]. Diabetes Obes Metab，2020，22（Suppl. 4）：14-23. tional，randomized，open-label，treat-to-target trial compa-
[15] ROSENSTOCK J，ARONSON R，GRUNBERGER G， ring insulin degludec and insulin glargine in insulin-Naïve
et al. Benefits of LixiLan，a titratable fixed-ratio combina‐ patients with type 2 diabetes mellitus[J]. Drugs R D，
tion of insulin glargine plus lixisenatide，versus insulin 2016，16（2）：239-249.
glargine and lixisenatide monocomponents in type 2 diabetes [25] ASO Y，SUZUKI K，CHIBA Y，et al. Effect of insulin de‐
inadequately controlled on oral agents：the LixiLan-O ran‐ gludec versus insulin glargine on glycemic control and
domized trial[J]. Diabetes Care，2016，39（11）：2026-2035. daily fasting blood glucose variability in insulin-Naïve
[16] RIDDLE M C，FORST T，ARONSON R，et al. Adding Japanese patients with type 2 diabetes：I’D GOT trial[J].
once-daily lixisenatide for type 2 diabetes inadequately Diabetes Res Clin Pract，2017，130：237-243.
controlled with newly initiated and continuously titrated [26] RODBARD H W，CARIOU B，ZINMAN B，et al. Com‐
basal insulin glargine：a 24-week，randomized，placebo- parison of insulin degludec with insulin glargine in
controlled study（GetGoal-Duo 1）[J]. Diabetes Care， insulin-naive subjects with type 2 diabetes：a 2-year ran‐
2013，36（9）：2497-2503. domized，treat-to-target trial[J]. Diabet Med，2013，30
[17] KANETO H，TAKAMI A，SPRANGER R，et al. Efficacy （11）：1298-1304.
and safety of insulin glargine/lixisenatide fixed-ratio com‐ [27] TELLA S H，RENDELL M S. Glucagon-like polypeptide
bination（iGlarLixi） in Japanese patients with type 2 diabe‐ agonists in type 2 diabetes mellitus：efficacy and tolerabi-
tes mellitus inadequately controlled on basal insulin and lity，a balance[J]. Ther Adv Endocrinol Metab，2015，6
oral antidiabetic drugs：the LixiLan JP-L randomized clinical （3）：109-134.
trial[J]. Diabetes Obes Metab，2020，22（Suppl. 4）：3-13. [28] MADSBAD S. Review of head-to-head comparisons of
[18] ARODA V R，ROSENSTOCK J，WYSHAM C，et al. Effi‐ glucagon-like peptide-1 receptor agonists[J]. Diabetes
cacy and safety of LixiLan，a titratable fixed-ratio combi‐ Obes Metab，2016，18（4）：317-332.
nation of insulin glargine plus lixisenatide in type 2 diabe‐ [29] 王仙花，常连庆 . 德谷胰岛素及其复方制剂在 2 型糖尿
tes inadequately controlled on basal insulin and metfor‐ 病中的临床研究现状及进展[J]. 中国处方药，2022，20
min：the LixiLan-L randomized trial[J]. Diabetes Care， （10）：191-194.
2016，39（11）：1972-1980. [30] CAI X L，GAO X Y，YANG W J，et al. Comparison be‐
[19] KAWAGUCHI Y，HAJIKA Y，RINKA M，et al. Compari‐ tween insulin degludec/liraglutide treatment and insulin
son of efficacy and safety of insulin degludec/liraglutide glargine/lixisenatide treatment in type 2 diabetes：a sys‐
and insulin glargine U-100/lixisenatide in individuals with tematic review and meta-analysis[J]. Expert Opin Pharma‐
type 2 diabetes mellitus using professional continuous glu‐ cother，2017，18（17）：1789-1798.
cose monitoring[J]. J Diabetes Investig，2024，15（5）： （收稿日期：2024-10-22 修回日期：2025-02-20）
598-607. （编辑：刘明伟）
[20] GOUGH S C L，BODE B，WOO V，et al. Efficacy and

· 880 · China Pharmacy 2025 Vol. 36 No. 7 中国药房 2025年第36卷第7期